Shi, Lei http://orcid.org/0000-0003-1149-0474
Shen, William http://orcid.org/0000-0002-4394-7099
Davis, Mindy I.
Kong, Ke
Vu, Phuong
Saha, Supriya K.
Adil, Ramzi
Kreuzer, Johannes
Egan, Regina
Lee, Tobie D.
Greninger, Patricia
Shrimp, Jonathan H.
Zhao, Wei http://orcid.org/0000-0002-5772-8671
Wei, Ting-Yu
Zhou, Mi http://orcid.org/0000-0001-8144-3468
Eccleston, Jason
Sussman, Jonathan
Manocha, Ujjawal
Weerasekara, Vajira
Kondo, Hiroshi
Vijay, Vindhya
Wu, Meng-Ju http://orcid.org/0000-0001-6847-7065
Kearney, Sara E.
Ho, Jeffrey
McClanaghan, Joseph
Murchie, Ellen
Crowther, Giovanna S.
Patnaik, Samarjit
Boxer, Matthew B.
Shen, Min
Ting, David T. http://orcid.org/0000-0002-3261-2322
Kim, William Y. http://orcid.org/0000-0001-7922-2156
Stanger, Ben Z. http://orcid.org/0000-0003-0410-4037
Deshpande, Vikram http://orcid.org/0000-0003-4230-9308
Ferrone, Cristina R.
Benes, Cyril H. http://orcid.org/0000-0002-8751-9707
Haas, Wilhelm
Hall, Matthew D. http://orcid.org/0000-0002-5073-442X
Bardeesy, Nabeel http://orcid.org/0000-0003-3867-0416
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K99CA245194-01, P50 CA127003, P50 CA127003)
Cholangiocarcinoma Foundation, Christopher J. Wilke Memorial Research Fellowship MGH Fund for Medical Discovery Award
U.S. Department of Defense (W81XWH-17-1-0491, W81XWH-17-1-0491)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
V Foundation for Cancer Research (Translation Team Science Award)
TargetCancer Foundation
Article History
Received: 25 February 2021
Accepted: 3 February 2023
First Online: 13 March 2023
Competing interests
: Patent applications for the drug uses detailed in this manuscript have been filed by L.S. and N.B. N.B. reports research funding from Kinnate Biopharma, Taiho Oncology, Relay, Bristol Myers Squibb and Servier Laboratories. B.Z.S. has received consulting fees from Boehringer-Ingelheim and iTeos Therapeutics. D.T.T. is a founder of and owns equity in TellBio, Inc., ROME Therapeutics and PanTher Therapeutics and has received consulting fees from Merrimack Pharmaceuticals, Ventana Roche, Foundation Medicine, Inc., and EMD Millipore Sigma. The other authors declare no other competing interests.
Free to read: This content has been made available to all.